SCHEMBL20069571

SCHEMBL20069571

Cc1cccc(C(=O)N2C3CC2CN(C)C3)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.44
P2RX7 Q99572 1/20 0.42
KMT2A Q03164 2/20 0.41
RET P07949 1/20 0.40
GRM5 P41594 3/20 0.40
CNR2 P34972 1/20 0.39
PDE2A O00408 1/20 0.39
DUSP3 P51452 1/20 0.38
PTPN11 Q06124 1/20 0.38
MEN1 O00255 1/20 0.38
SORT1 Q99523 1/20 0.37
CSF1R P07333 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
TSHR P16473 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20148708 0.85 PDE10A (0.42) PDE10AP2RX7KMT2ARETGRM5
SCHEMBL20070578 0.82 MGLL (0.45) RET
SCHEMBL20069577 0.78 L3MBTL1 (0.51) PDE10AKMT2ARETGRM5ALDH1A1
SCHEMBL20069581 0.77 TDP1 (0.44) PDE10ARETCSF1RMAPTRAB9A
SCHEMBL20069573 0.73 PDE10A (0.46) PDE10ARETGRM5PDE2ACSF1R
SCHEMBL22030882 0.73 NNMT (0.46) KMT2ARETALDH1A1GAA
SCHEMBL20069586 0.71 HDAC1 (0.43) KMT2ARETGRM5CNR2PDE2A
SCHEMBL20069583 0.70 PDE10A (0.46) PDE10ARETGRM5PDE2ACSF1R
SCHEMBL20069584 0.70 P2RX7 (0.43) P2RX7KMT2ARETPDE2AMEN1
SCHEMBL18254471 0.69 GNE (0.63) PDE10AP2RX7KMT2AGRM5CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3753939-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma Inc. (US) 2020-12-23 EP disclosed
EP-3523301-B1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-05-27 EP disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
WO-2018071447-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF PDE10A 822/4885P2RX7 1487/4885KMT2A 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.